Search results for SLC22A2

Showing 6 results out of 6

×

Species

Types

Compartments

Search properties

Species

Types

Compartments

Search properties

Protein (1 results from a total of 1)

Identifier: R-HSA-374914
Species: Homo sapiens
Compartment: plasma membrane
Primary external reference: UniProt: SLC22A2: O15244

Set (1 results from a total of 1)

Identifier: R-HSA-2901780
Species: Homo sapiens
Compartment: plasma membrane
This CandidateSet contains sequences identified by William Pearson's analysis of Reactome catalyst entities. Catalyst entity sequences were used to identify analagous sequences that shared overall homology and active site homology. Sequences in this Candidate set were identified in an April 24, 2012 analysis.

Interactor (1 results from a total of 1)

Identifier: A1A5C7-2
Species: Homo sapiens
Primary external reference: UniProt: A1A5C7-2

Reaction (3 results from a total of 3)

Identifier: R-HSA-2161500
Species: Homo sapiens
Compartment: cytosol, plasma membrane, extracellular region
Organic cation transporters 1 (OCT1, SLC22A1), 2 (OCT2, SLC22A2) and 3 (OCT3, SLC22A3) associated with the plasma membrane all mediate the influx of abacavir. The three transporters have similar affinities for abacavir (Minuesa et al. 2009) but differ in the tissues in which they are expressed and in their distributions on the surfaces of polarized cells (reviewed by Klaasen and Aleksunes 2010).
Identifier: R-HSA-561054
Species: Homo sapiens
Compartment: plasma membrane
The human gene SLC22A2 encodes the organic cation transporter OCT2. It is expressed in a variety of tissues, especially the kidney and placenta. OCT2 can mediate the reversible transport of a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN) and 4-(4-(dimethylamino)styryl)-N-methylpyridinium (Gorboulev et al. 1997). Pharmaceuticals that up-regulate OCT2 in the kidney can increase the renal excretion of cationic drugs. The transport activity of OCT2 was decreased upon co-expression of regulatory solute carrier protein family 1 member 1 (RSC1A1, aka RS1). RSC1A1 exhibits glucose-dependent, short-term inhibition of OCT2 by inhibiting the release of vesicles from the trans-Golgi network (Veyhl et al. 2006).
Identifier: R-HSA-549279
Species: Homo sapiens
Compartment: plasma membrane
The human gene SLC22A2 encodes the organic cation transporter OCT2. It is expressed in a variety of tissues, especially the kidney and placenta. OCT2 can mediate the reversible transport of a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN) and 4-(4-(dimethylamino)styryl)-N-methylpyridinium (Gorboulev et al. 1997). Pharmaceuticals that up-regulate OCT2 in the kidney can increase the renal excretion of cationic drugs. The transport activity of OCT2 was decreased upon co-expression of regulatory solute carrier protein family 1 member 1 (RSC1A1, aka RS1). RSC1A1 exhibits glucose-dependent, short-term inhibition of OCT2 by inhibiting the release of vesicles from the trans-Golgi network (Veyhl et al. 2006).
Cite Us!